首页> 美国卫生研究院文献>Frontiers in Genetics >The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy
【2h】

The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy

机译:端粒酶复合物直接控制造血干细胞分化和衰老诱导端粒病变的多能干细胞模型中。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Telomeropathies are rare disorders associated with impaired telomere length control mechanisms that frequently result from genetic mutations in the telomerase complex. Dyskeratosis congenita is a congenital progressive telomeropathy in which mutation in the telomerase RNA component (TERC) impairs telomere maintenance leading to accelerated cellular senescence and clinical outcomes resembling premature aging. The most severe clinical feature is perturbed hematopoiesis and bone-marrow failure, but the underlying mechanisms are not fully understood. Here, we developed a model of telomerase function imbalance using shRNA to knockdown TERC expression in human induced pluripotent stem cells (iPSCs). We then promoted in vitro hematopoiesis in these cells to analyze the effects of TERC impairment. Reduced TERC expression impaired hematopoietic stem-cell (HSC) differentiation and increased the expression of cellular senescence markers and production of reactive oxygen species. Interestingly, telomere length was unaffected in shTERC knockdown iPSCs, leading to conclusion that the phenotype is controlled by non-telomeric functions of telomerase. We then assessed the effects of TERC-depletion in THP-1 myeloid cells and again observed reduced hematopoietic and myelopoietic differentiative potential. However, these cells exhibited impaired telomerase activity as verified by accelerated telomere shortening. shTERC-depleted iPSC-derived and THP-1-derived myeloid precursors had lower phagocytic capacity and increased ROS production, indicative of senescence. These findings were confirmed using a BIBR1532 TERT inhibitor, suggesting that these phenotypes are dependent on telomerase function but not directly linked to telomere length. These data provide a better understanding of the molecular processes driving the clinical signs of telomeropathies and identify novel roles of the telomerase complex other than regulating telomere length.
机译:端粒病是与端粒长度控制机制受损有关的罕见疾病,通常是端粒酶复合物的基因突变导致的。先天性角化病是一种先天性进行性端粒病,其中端粒酶RNA成分(TERC)的突变会削弱端粒的维持,导致加速的细胞衰老和类似于早衰的临床结果。最严重的临床特征是造血功能紊乱和骨髓衰竭,但其潜在机制尚不完全清楚。在这里,我们建立了端粒酶功能失衡的模型,使用shRNA敲低人类诱导的多能干细胞(iPSC)中的TERC表达。然后,我们在这些细胞中促进了体外造血作用,以分析TERC损伤的影响。减少的TERC表达削弱了造血干细胞(HSC)的分化,并增加了细胞衰老标记的表达和活性氧的产生。有趣的是,在shTERC敲低的iPSC中,端粒的长度不受影响,从而得出结论,该表型受端粒酶的非端粒功能控制。然后,我们评估了THP-1髓样细胞中TERC消耗的影响,并再次观察到造血和骨髓生成分化潜能的降低。然而,这些细胞表现出端粒酶活性受损,这通过加速端粒缩短来证明。 shTERC耗尽的iPSC来源和THP-1来源的髓样前体具有较低的吞噬能力,​​并增加了ROS的产生,表明衰老。使用BIBR1532 TERT抑制剂证实了这些发现,表明这些表型取决于端粒酶功能,但不直接与端粒长度相关。这些数据更好地理解了驱动端粒病临床体征的分子过程,并鉴定了端粒酶复合物的新作用,而不是调节端粒的长度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号